Low immunogenicity of insulin efsitora alfa in participants with type 1 and type 2 diabetes mellitus
Open Access
- 4 December 2025
- journal article
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 28 (2) , 1350-1358
Abstract
Aims: To evaluate treatment‐emergent antidrug antibodies (TE ADA) in once‐weekly basal insulin efsitora‐treated participants with type 1 and type 2 diabetes mellitus (T1DM and T2DM) from 5 phase 3 clinical trials and their potential impact on pharmacokinetics, efficacy and safety. Materials and Methods: Serum samples were collected at baseline and throughout the studies. ADA were measured and characterised for their cross‐reactivity to native insulin or ability to neutralise efsitora or endogenous insulin. ADA impact on the pharmacokinetics, efficacy and safety of efsitora was evaluated by comparing the clearance of efsitora, glycated haemoglobin (HbA1c) change from baseline at the primary endpoint, and incidence of treatment‐emergent hypersensitivity reactions or injection site reactions by ADA status, respectively. Results: About 0.6% and 3.0% of efsitora‐treated participants with T1DM (341) and T2DM (1861), respectively, developed TE ADA. Cross‐reactive antibodies to native insulin and neutralising antibodies against efsitora and native insulin were observed in 1.7%, 1.1% and 0.8% of efsitora‐treated participants with T2DM, respectively, but not in those with T1DM. Maximum ADA titres ranged from 1:40 to 1:81 920, with a median of 1:80. The clearance of efsitora was similar between baseline ADA+ and ADA− groups. TE ADA status did not significantly affect HbA1c reduction or cause hypersensitivity or injection site reactions in efsitora‐treated participants. Conclusions: Efsitora caused an immunogenic response in up to 3.0% of participants with T1DM and T2DM. Descriptive analysis indicates that the immunogenicity of efsitora did not noticeably impact its pharmacokinetics, efficacy or safety. The molecular design of efsitora may contribute to its low immunogenicity.Keywords
Funding Information
- Eli Lilly and Company
This publication has 42 references indexed in Scilit:
- A competitive ligand binding assay for detection of neutralizing antibodies against an insulin analogJournal of Immunological Methods, 2023
- Immunogenicity, Efficacy, and Safety of Biosimilar Insulin Aspart (MYL-1601D) Compared with Originator Insulin Aspart (Novolog®) in Patients with Type 1 Diabetes After 24 Weeks: A Randomized Open-Label StudyBioDrugs, 2022
- A Model‐Based Approach to Quantify the Time‐Course of Anti‐Drug Antibodies for Therapeutic ProteinsClinical Pharmacology & Therapeutics, 2018
- Affinity capture elution bridging assay: A novel immunoassay format for detection of anti-therapeutic protein antibodiesJournal of Immunological Methods, 2016
- Insulin Aspart in the Management of Diabetes Mellitus: 15 Years of Clinical ExperienceDrugs, 2015
- γδ T cells recognize the insulin B:9–23 peptide antigen when it is dimerized through thiol oxidationMolecular Immunology, 2014
- Neonatal Fc Receptor: From Immunity to TherapeuticsJournal of Clinical Immunology, 2010
- Priming and boosting determinants on the antibody response to an Epidermal Growth Factor-based cancer vaccineVaccine, 2008
- A case of slowly progressive type 1 diabetes with unstable glycemic control caused by unusual insulin antibody and successfully treated with steroid therapyDiabetes Research and Clinical Practice, 2006
- Immunogenicity of interferon-? in multiple sclerosis patients: Influence of preparation, dosage, dose frequency, and route of administrationAnnals of Neurology, 2000